These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19302537)

  • 1. Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.
    Wondergem MJ; Grünberg K; Wittgen BP; Sonneveld P; Zweegman S
    Histopathology; 2009 Apr; 54(5):631-3. PubMed ID: 19302537
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pneumocystis jirovecii Pneumonia in a Patient with Interstitial Lung Disease].
    Özkoç S; Alpaydın AÖ; Delibaş SB; Ergüden C; Akkoçlu A
    Turkiye Parazitol Derg; 2015 Mar; 39(1):66-9. PubMed ID: 25917588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
    Piro E; Kropp M; Cantaffa R; Lamberti AG; Carillio G; Molica S
    Ann Hematol; 2012 Nov; 91(11):1827-8. PubMed ID: 22584850
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful bone reconstruction after bortezomib therapy in a myeloma patient.
    Tanaka T; Yamasaki R; Omura H; Hino N
    Int J Hematol; 2011 Sep; 94(3):221. PubMed ID: 21861100
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
    Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of bortezomib on bone disease in multiple myeloma.
    Drake MT; Rajkumar SV
    Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
    [No Abstract]   [Full Text] [Related]  

  • 7. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
    Wang HH; Tsui J; Wang XY; Liu SS; Li J
    Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
    [No Abstract]   [Full Text] [Related]  

  • 8. Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.
    Siniscalchi A; Dentamaro T; Perrotti A; Tatangelo P; de Fabritiis P; Caravita T
    Ann Hematol; 2010 Aug; 89(8):821-2. PubMed ID: 19953253
    [No Abstract]   [Full Text] [Related]  

  • 9. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
    Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A
    Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298
    [No Abstract]   [Full Text] [Related]  

  • 10. Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.
    Minarik J; Scudla V; Tichy T; Pika T; Bacovsky J; Lochman P; Zadrazil J
    Leuk Lymphoma; 2012 Feb; 53(2):330-1. PubMed ID: 21883030
    [No Abstract]   [Full Text] [Related]  

  • 11. Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment.
    Szturz P; Adam Z; Vašků V; Feit J; Krejčí M; Pour L; Hájek R; Mayer J
    Leuk Lymphoma; 2013 Jun; 54(6):1324-6. PubMed ID: 23061634
    [No Abstract]   [Full Text] [Related]  

  • 12. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
    Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
    Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
    [No Abstract]   [Full Text] [Related]  

  • 13. Concurrent radiation therapy and bortezomib in myeloma patient.
    Berges O; Decaudin D; Servois V; Kirova YM
    Radiother Oncol; 2008 Feb; 86(2):290-2. PubMed ID: 18199515
    [No Abstract]   [Full Text] [Related]  

  • 14. Breathless on bortezomib.
    O'Riordan D; Houghton J; Chisholm R; O'Driscoll BR
    BMJ Case Rep; 2011 Aug; 2011():. PubMed ID: 22688931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.
    Zappasodi P; Dore R; Castagnola C; Astori C; Varettoni M; Mangiacavalli S; Lazzarino M; Corso A
    J Clin Oncol; 2007 Aug; 25(22):3380-1. PubMed ID: 17664489
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
    Fröhlich K; Holle JU; Aries PM; Gross WL; Moosig F
    Ann Rheum Dis; 2011 Jul; 70(7):1344-5. PubMed ID: 21173019
    [No Abstract]   [Full Text] [Related]  

  • 17. Interstitial pneumonitis and coinfection of human herpesvirus 6 and Pneumocystis carinii in a patient with hypogammaglobulinemia.
    Vuorinen T; Kotilainen P; Lautenschlager I; Kujari H; Krogerus L; Oksi J
    J Clin Microbiol; 2004 Nov; 42(11):5415-8. PubMed ID: 15528760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
    Badros A; Gahres N
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib increases survival of patients with relapsed multiple myeloma.
    Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
    [No Abstract]   [Full Text] [Related]  

  • 20. Bortezomib therapy following first relapse.
    Orlowski RZ;
    Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.